Guard Therapeutics completes Disruptive Pharma reverse takeover, issues 24,420,434 shares at SEK 2.48 each

• Guard Therapeutics completed its acquisition of 99.07% of Disruptive Pharma, with Disruptive Pharma becoming a subsidiary.
• Consideration was paid via an in-kind issue of 24,420,434 new shares priced at about SEK 2.48 each.
• Post-issue ownership shifts to about 54.77% for former Disruptive Pharma shareholders, leaving existing Guard Therapeutics shareholders with about 45.23%.
• The share issue raises share capital by SEK 6,105,109 to SEK 11,147,016, increasing total shares outstanding to 44,588,065.
• The group plans to buy the remaining Disruptive Pharma shares on the same terms, with 4,884,086 consideration shares held in escrow for seven months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guard Therapeutics International AB (publ) published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein.